Association of TGF-β1 with cystatin-C in patients with diabetic nephropathy

Background however, only TGF-β 1-3 has been demonstrated to be expressed in mammals. Methodology: The current research comprised of a total of 130 individuals, all of whom were placed into one of three primary groups ; 50 (25 males and 25 females) diabetic patients without nephropathy; 50 (25 males and 25 females) diabetic patients with nephropathy as cases, and 30 (15 males and 15 females) persons in good health, who were of the same age as the patients being studied. In order to measure the concentrations of the parameters, the standard procedures and techniques were used. Results: The mean value of serum TGF-β1was significantly higher in diabetic patients without nephropathy and diabetic patients with nephropathy (40.19 ± 3.56 ng/ml),(51.21 ± 5.20 ng/ml) respectively as compared to controls (24.80 ± 3.51 ng/ml) with a high significant difference (P 0.05), which may be due to the fact that the level of TGF 1 rises with increasing duration of the participant's cases. Conclusion: There is no significant correlation between cystatin-C with fasting blood sugar. There was a statistically significant and positive link between the blood TGF-β1 levels and the serum creatinine and cystatin-C levels. Key words: Type-2 Diabetes Mellitus; TGF-β1; Cystatin-C. Citation: Jasem AH, Haddad NS, Yaseen NT. Association of TGF-β1 with cystatin-C in patients with diabetic nephropathy. Anaesth. pain intensive care 2024;28(1):151−154; DOI: 10.35975/apic.v28i1.2399 Received: October 26, 2023; Reviewed: December 11, 2023; Accepted: December 11, 2023